4-(3-hydroxyphenyl)but-3-en-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 4-(3-hydroxyphenyl)but-3-en-2-one
• 英文别名: meta-hydroxybenzalacetone；m-Hydroxybenzalaceton；Methyl-(3-hydroxy-styryl)-keton；3-Hydroxybenzylidenaceton；4-(3-Hydroxy-phenyl)-but-3-en-2-on；3-hydroxybenzylideneacetone；1-(3-Hydroxyphenyl)but-1-en-3-one
• 化学式: C₁₀H₁₀O₂
• 分子量: 162.188
• InChiKey: BQQMTVHCRIOEDO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-hydroxyphenyl)but-3-en-2-one 在 palladium 10% on activated carbon 、 氢气 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 20.0 ℃ 、202.66 kPa 条件下， 反应 1.67h， 生成 3-(3-hydroxy-3-methylbutyl)phenol
  参考文献：
  名称：

  8-Hydroxyquinolin-2(1H)-one 类似物作为潜在的 β2-激动剂：设计、合成和活性研究

  摘要：

  与导致 cAMP 积累的质膜β 2 -肾上腺素受体结合的β 2 -激动剂被广泛用作慢性呼吸系统疾病中的支气管扩张剂。在这里，我们设计并合成了一组 8-hydroxyquinolin-2(1 H )-one 类似物，并通过细胞 cAMP 测定研究了它们的 β 2 -激动活性。在测试的化合物中，化合物B05和C08被确定为有效的 (EC 50  < 20 pM) 和选择性 β 2 -激动剂。它们表现为部分 β 2β-激动剂在非过表达的 HEK293 细胞中，并在离体豚鼠气管条制剂中具有快速平滑肌松弛作用和长作用持续时间。综上所述，B05和C08是具有潜在适用于慢性呼吸道疾病的 β 2 -激动剂。

  DOI：

  10.1016/j.ejmech.2021.113697
• 作为产物：
  描述：

  间羟基苯甲醛 以86的产率得到4-(3-hydroxyphenyl)but-3-en-2-one
  参考文献：
  名称：

  J. Med. Chem. 2007, 50, 550-565

  摘要：

  DOI：

文献信息

• Hydrogen-transfer reduction of α,β-unsaturated carbonyl compounds catalyzed by naphthyridine-functionalized N-heterocyclic carbene complexes
  作者：Hsiao-Ching Huang、Mani Ramanathan、Yi-Hong Liu、Shie-Ming Peng、Shiuh-Tzung Liu

  DOI：10.1002/aoc.3673

  日期：2017.8

  confirmed using X‐ray crystallography. In catalytic activity studies, complex 5 was found to be an effective catalyst in the hydrogen‐transfer reduction of α,β‐unsaturated carbonyl compounds into the corresponding saturated carbonyl compounds.

  银络合物的2-氯-7-（mesitylimidazolylidenylmethyl）萘啶（NpNHC）与钯（II），提供[钯（铑（I）和铱（I）的金属前体的取代Ç，Ñ -NpNHC）（η 3 -烯丙基）]（BF 4）（5），RhCl（COD）（C -NpNHC）（6a）和IrCl（COD）（C -NpNHC）（6b）。用AgBF 4从6a和6b提取氯提供了螯合配合物[Rh（COD）（C，N- NpNHC）]（BF 4）（7a）和Ir（COD）（C，N‐ NpNHC）（BF 4）（7b）。使用NMR和元素分析对所有复合物进行表征，并使用X射线晶体学进一步证实5a和6a的结构细节。在催化活性研究中，发现配合物5是将α，β-不饱和羰基化合物氢转移还原为相应的饱和羰基化合物的有效催化剂。
• 1,5-DIPHENYL-PENTA-1,4-DIEN-3-ONE COMPOUNDS
  申请人：Shih Charles C-Y

  公开号：US20120046247A1

  公开（公告）日：2012-02-23

  This invention relates to compounds of Formula (I), (II), or (III) as shown in the specification, which contain a 1,5-diphenylpenta-1,4-dien-3-one backbone. These compounds can be used to treat cancer, inflammatory disease, or autoimmune disease.

  这项发明涉及到规范中所示的具有Formula (I)、(II)或(III)的化合物，这些化合物含有1,5-二苯基戊-1,4-二烯-3-酮骨架。这些化合物可用于治疗癌症、炎症性疾病或自身免疫疾病。
• Organocatalytic Enantioselective Michael Addition of 4-Hydroxycoumarin to α,β-Unsaturated Ketones: A Simple Synthesis of Warfarin
  作者：Zhenhua Dong、Lijia Wang、Xiaohong Chen、Xiaohua Liu、Lili Lin、Xiaoming Feng

  DOI：10.1002/ejoc.200900831

  日期：2009.10

  secondary amine amide catalysts were developed for the asymmetric Michael addition of 4-hydroxycoumarin to α,β-unsaturated ketones. A series of important biologically and pharmaceutically active compounds were obtained in excellent yields (up to 99 %) with high enantioselectivities (up to 89 % ee) under mild conditions. In addition, enantiopure product could be obtained by a single recrystallization

  开发了一种 C2 对称仲胺酰胺催化剂，用于 4-羟基香豆素与 α,β-不饱和酮的不对称迈克尔加成。在温和的条件下，以优异的收率（高达 99%）和高对映选择性（高达 89% ee）获得了一系列重要的生物和药物活性化合物。此外，单次重结晶可以得到对映体纯的产物。(© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim, Germany, 2009)
• Preparation of prodrugs for selective drug delivery
  申请人：Mills L. Randell

  公开号：US20050080260A1

  公开（公告）日：2005-04-14

  Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.

  合成具有A-B-C化学式的化合物，可用于药物传递等应用，其中A是化学发光基团，B是光致变色基团，C是生物活性基团，其中A-B-C可作为前药。本发明的新型合成方法用于形成前药，包括以下步骤：(1)形成苯酮，(2)形成二芳基乙烯，(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上，形成邻苯二甲酰亚胺-乙烯共轭物，(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物，形成邻苯二甲酰亚胺-戊二烯共轭物，(5)通过与肼反应将邻苯二甲酰亚胺转化为邻苯二酰肼，形成本发明的载体化合物，(6)将载体化合物与药物的亲核基团反应，形成相应的前药。另外，可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后，通过与亲核试剂反应保护阳离子类似化合物，并通过钯催化的胺化与氨基邻苯二甲酰亚胺偶联，形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与肼回流，将其邻苯二甲酰亚胺转化为邻苯二酰肼，并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂，用于治疗病毒感染，如HIV，以及用作抗癌剂，用于治疗结肠癌、肺癌和乳腺癌等癌症。
• Catalytic asymmetric synthesis of chiral phenols in ethanol with recyclable rhodium catalyst
  作者：Jian Yao、Na Liu、Long Yin、Junhao Xing、Tao Lu、Xiaowei Dou

  DOI：10.1039/c9gc02420d

  日期：——

  A general method to access diverse chiral phenols by rhodium-catalyzed asymmetric conjugate arylation using hydroxylated arylboronic acids in ethanol was developed. Recycling of the rhodium catalyst by flash chromatography on silica gel was feasible in this system. The synthetic utility of the strategy was demonstrated by efficient synthesis of chiral drug tolterodine.

  建立了在乙醇中使用羟基化的芳基硼酸通过铑催化的不对称共轭芳基化反应获得各种手性酚的通用方法。在该系统中通过快速色谱法在硅胶上回收铑催化剂是可行的。通过手性药物托特罗定的有效合成证明了该策略的合成效用。